Rare clinical case: Autoimmune hepatitis type 3
https://doi.org/10.31146/1682-8658-ecg-177-5-120-126
Abstract
Background. The fi rst clinical case of autoimmune hepatitis (AIH) was described in 1951, and in the 1970s, several randomized clinical trials proved the eff ectiveness of glucocorticosteroids in the treatment of AIH. Nonetheless, this disease remains a mystery to clinicians due to its rarity and heterogeneity.
Aim. To describe the clinical case of the patient with AIH (SLA/LP antibodies) and discuss its management.
Clinical case. A 22-year-old male with an acute manifestation of autoimmune hepatitis and a delayed, isolated increase of autoantibodies (SLA/LP). The initial diagnosis was made based on hypergammaglobulinemia and the eff ectiveness of glucocorticosteroids. Highly specifi c antibodies were detected only after 3.5 months, and the AIH was confi rmed histologically.
Conclusion. This clinical case emphasizes the need to isolate type 3 AIH due to the more severe course and common relapse after the withdrawal of immunosuppressive therapy.
About the Authors
M. E. Zharova
N. I. Pirogov Russian National Research Medical University (a Federal Government-funded Educational Institution of Higher Education), Russian Ministry of Health; Research Institute for Healthcare Organization and Medical Management (a Government-funded Institution), Moscow City Department of Health
Russian Federation
Russian Federation
Maria E. Zharova, MD, MSc
1 Ostrovityanov St., Moscow, 117997
30 Bolshaya Tatarskaya St., Moscow, 115184
Yu. V. Grigoreva
N. I. Pirogov Russian National Research Medical University (a Federal Government-funded Educational Institution of Higher Education), Russian Ministry of Health; Federal State Budgetary Institution “Central Clinical Hospital”, of the Russian Federation Presidential Administration
Russian Federation
Russian Federation
Yuliya V. Grigoreva, MD, PhD
1 Ostrovityanov St., Moscow, 117997
Moscow, 15 Marshal Tymoshenko St. 121359
E. L. Nikonov
N. I. Pirogov Russian National Research Medical University (a Federal Government-funded Educational Institution of Higher Education), Russian Ministry of Health
Russian Federation
Russian Federation
Evgeni L. Nikonov, MD, PhD
1 Ostrovityanov St., Moscow, 117997
I. O. Ivanikov
N. I. Pirogov Russian National Research Medical University (a Federal Government-funded Educational Institution of Higher Education), Russian Ministry of Health; Federal State Budgetary Institution “Central Clinical Hospital”, of the Russian Federation Presidential Administration
Russian Federation
Russian Federation
Igor O. Ivanikov, MD, PhD
1 Ostrovityanov St., Moscow, 117997
Moscow, 15 Marshal Tymoshenko St. 121359
O. S. Grebneva
Federal State Budgetary Institution “Central Clinical Hospital”, of the Russian Federation Presidential Administration
Russian Federation
Russian Federation
Olga S. Grebneva, MD, PhD
Moscow, 15 Marshal Tymoshenko St. 121359
References
1. Ивашкин ВТ, Буеверов АО, Маевская МВ, Абдул га ниева ДИ. Клинические рекомендации по диагностике и лечению аутоиммунного гепатита. Министерство здравоохранения Российской Федерации. 2013. Iva shkin V T, Bue ve rov AO, Mae vsk aya MV, Abdulganieva DI. Klinicheskie rekomendacii po diagnostike i lecheniyu autoimmunnogo gepatita. Ministerstvo zdravoohraneniya Rossijskoj Federacii. 2013.(In Russ.
2. Gleeson D, Heneghan MA, Gastroenterology BSo. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut. 2011;60(12):1611– 29. https://doi.org/10.1136/gut.2010.235259
3. Wiley-Blackwell. Yamada’s Textbook of Gastroenterology. 6 th Edition ed: Wiley; 2016:3440.
4. Одинцова А.Х., Абдулганиева Д. И., Черемина Н. А., Ибрагимова А. В. Региональные клинико-эпидемиологические особенности аутоиммунных заболеваний печени. Практическая медицина. 2011;55:214–5. Odintsova А. H., Abdulganieva D. I., Cheremina N. A., Ibragimova А. V. Regional clinico-epidemiological features of autoimmune liver diseases. Prakticheskaya medicina.2011;55:214–5 (In Russ.)
5. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. Journal of Hepatology. 1999;31(5):929–38. https://doi.org/10.1016/s0168-8278(99)80297-9
6. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48(1):169–176. https://doi.org/10.1002/hep.22322
7. Арутюнов А.Т., Иваников И. О., Сюткин В. Е. Диагностика и лечение хронических заболеваний печени (руководство). Москва: ПРИНТ-АТЕЛЬЕ; 2005. Arutyunov A. T., Ivanikov I. O., Syutkin V. E. Diagnostika i lechenie hronicheskih zabolevanij pecheni (rukovodstvo). Moskva: PRINT-ATEL’E; 2005 (In Russ.)
8. EASL Clinical Practice Guidelines: Autoimmune hepatitis. Journal of Hepatology. 2015;63(4):971–1004. https://doi.org/10.1016/j.jhep.2015.06.030
9. Zachou K, Weiler-Normann C, Muratori L, Muratori P, Lohse AW, Dalekos GN. Permanent immunosuppression in SLA/LP-positive autoimmune hepatitis is required although overall response and survival are similar. Liver International. 2020;40(2):368–376. https://doi.org/10.1111/liv.14280
10. Liver Tox: Clinical and Research Information on DrugInduced Liver Injury. Thyroid Hormone [Text]. National Institute of Diabetes and Digestive and Kidney Diseases; 2019 [updated 2019/04/15]. Accessed January 6, 2020. Available from: https://www.ncbi.nlm.nih.gov/pubmed/.
11. Hlaihel AF, Al-Khairalla MZH. Levothyroxine-induced liver injury followed by complete recovery upon cessation of the drug: a case report. Journal of Medical Case Reports. 2019;13(1):311. https://doi.org/10.1186/s13256-019-2244-z
12. Sebode M, Weiler-Normann C, Liwinski T, Schramm C. Autoantibodies in Autoimmune Liver DiseaseClinical and Diagnostic Relevance. Frontiers in Immunology.2018;9:609. https://doi.org/10.3389/fimmu.2018.00609
13. Lowe D, John S. Autoimmune hepatitis: Appraisal of current treatment guidelines. World Journal of Hepatology. 2018;10(12):911–23. https://doi.org/10.4254/wjh.v10.i12.911
14. Zachou K, Gampeta S, Gatselis NK, et al. Anti-SLA/LP alone or in combination with anti-Ro52 and fine specificity of anti-Ro52 antibodies in patients with autoimmune hepatitis. Liver International. 2015;35(2):660–72. https://doi.org/10.1111/liv.12658
15. Chen ZX, Shao JG, Shen Y, Zhang J, Hua Y, Wang LJ, Qin G. Prognostic Implications of Antibodies to Soluble Liver Antigen in Autoimmune Hepatitis: A PRISMA-Compliant Meta-Analysis. Medicine (Baltimore). 2015;94(23): e953. https://doi.org/10.1097/MD.0000000000000953
Review
For citations:
Zharova M.E., Grigoreva Yu.V., Nikonov E.L., Ivanikov I.O., Grebneva O.S. Rare clinical case: Autoimmune hepatitis type 3. Experimental and Clinical Gastroenterology. 2020;174(5):120-126. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-177-5-120-126
Views:
677
Email this article 